Targeting cellular cathepsins inhibits hepatitis E virus entry

Background and Aims: - HEV is estimated to be responsible for 70,000 deaths annually, yet therapy options remain limited. In the pursuit of effective antiviral therapies, targeting viral entry holds promise and has proven effective for other viruses. However, the precise mechanisms and host facto...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Klöhn, Mara (VerfasserIn) , Burkard, Thomas (VerfasserIn) , Janzen, Juliana (VerfasserIn) , Haase, Jil A. (VerfasserIn) , Gömer, André (VerfasserIn) , Fu, Rebecca Menhua (VerfasserIn) , Ssebyatika, George (VerfasserIn) , Nocke, Maximilian K. (VerfasserIn) , Brown, Richard J. P. (VerfasserIn) , Krey, Thomas (VerfasserIn) , Dao Thi, Viet Loan (VerfasserIn) , Kinast, Volker (VerfasserIn) , Brüggemann, Yannick (VerfasserIn) , Todt, Daniel (VerfasserIn) , Steinmann, Eike (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: November 2024
In: Hepatology
Year: 2024, Jahrgang: 80, Heft: 5, Pages: 1239-1251
ISSN:1527-3350
DOI:10.1097/HEP.0000000000000912
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1097/HEP.0000000000000912
Verlag, kostenfrei, Volltext: https://journals.lww.com/hep/fulltext/2024/11000/targeting_cellular_cathepsins_inhibits_hepatitis_e.26.aspx
Volltext
Verfasserangaben:Mara Klöhn, Thomas Burkard, Juliana Janzen, Jil A. Haase, André Gömer, Rebecca Fu, George Ssebyatika, Maximilian K. Nocke, Richard J.P. Brown, Thomas Krey, Viet Loan Dao Thi, Volker Kinast, Yannick Brüggemann, Daniel Todt, Eike Steinmann

MARC

LEADER 00000caa a2200000 c 4500
001 1909529648
003 DE-627
005 20251022121313.0
007 cr uuu---uuuuu
008 241126s2024 xx |||||o 00| ||eng c
024 7 |a 10.1097/HEP.0000000000000912  |2 doi 
035 |a (DE-627)1909529648 
035 |a (DE-599)KXP1909529648 
035 |a (OCoLC)1475648198 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 32  |2 sdnb 
100 1 |a Klöhn, Mara  |e VerfasserIn  |0 (DE-588)1231844183  |0 (DE-627)1755476752  |4 aut 
245 1 0 |a Targeting cellular cathepsins inhibits hepatitis E virus entry  |c Mara Klöhn, Thomas Burkard, Juliana Janzen, Jil A. Haase, André Gömer, Rebecca Fu, George Ssebyatika, Maximilian K. Nocke, Richard J.P. Brown, Thomas Krey, Viet Loan Dao Thi, Volker Kinast, Yannick Brüggemann, Daniel Todt, Eike Steinmann 
264 1 |c November 2024 
300 |b Illustrationen 
300 |a 13 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 26.11.2024 
520 |a Background and Aims: - HEV is estimated to be responsible for 70,000 deaths annually, yet therapy options remain limited. In the pursuit of effective antiviral therapies, targeting viral entry holds promise and has proven effective for other viruses. However, the precise mechanisms and host factors required during HEV entry remain unclear. Cellular proteases have emerged as host factors required for viral surface protein activation and productive cell entry by many viruses. Hence, we investigated the functional requirement and therapeutic potential of cellular protease during HEV infection. - Approach and Results: - Using our established HEV cell culture model and subgenomic HEV replicons, we found that blocking lysosomal cathepsins (CTS) with small molecule inhibitors impedes HEV infection without affecting replication. Most importantly, the pan-cathepsin inhibitor K11777 suppressed HEV infections with an EC50 of ~0.02 nM. Inhibition by K11777, devoid of notable toxicity in hepatoma cells, was also observed in HepaRG and primary human hepatocytes. Furthermore, through time-of-addition and RNAscope experiments, we confirmed that HEV entry is blocked by inhibition of cathepsins. Cathepsin L (CTSL) knockout cells were less permissive to HEV, suggesting that CTSL is critical for HEV infection. Finally, we observed cleavage of the glycosylated ORF2 protein and virus particles by recombinant CTSL. - Conclusions: - In summary, our study highlights the pivotal role of lysosomal cathepsins, especially CTSL, in the HEV entry process. The profound anti-HEV efficacy of the pan-cathepsin inhibitor K11777, especially with its notable safety profile in primary cells, further underscores its potential as a therapeutic candidate. 
700 1 |a Burkard, Thomas  |e VerfasserIn  |4 aut 
700 1 |a Janzen, Juliana  |e VerfasserIn  |4 aut 
700 1 |a Haase, Jil A.  |e VerfasserIn  |4 aut 
700 1 |a Gömer, André  |e VerfasserIn  |4 aut 
700 1 |a Fu, Rebecca Menhua  |d 1993-  |e VerfasserIn  |0 (DE-588)1214598528  |0 (DE-627)1725566583  |4 aut 
700 1 |a Ssebyatika, George  |e VerfasserIn  |4 aut 
700 1 |a Nocke, Maximilian K.  |e VerfasserIn  |4 aut 
700 1 |a Brown, Richard J. P.  |e VerfasserIn  |4 aut 
700 1 |a Krey, Thomas  |e VerfasserIn  |4 aut 
700 1 |a Dao Thi, Viet Loan  |e VerfasserIn  |0 (DE-588)1186079657  |0 (DE-627)1665348402  |4 aut 
700 1 |a Kinast, Volker  |e VerfasserIn  |4 aut 
700 1 |a Brüggemann, Yannick  |e VerfasserIn  |4 aut 
700 1 |a Todt, Daniel  |e VerfasserIn  |4 aut 
700 1 |a Steinmann, Eike  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t Hepatology  |d [Alphen aan den Rijn] : Wolters Kluwer Health, 1981  |g 80(2024), 5 vom: Okt., Seite 1239-1251  |h Online-Ressource  |w (DE-627)268132003  |w (DE-600)1472120-X  |w (DE-576)077450183  |x 1527-3350  |7 nnas  |a Targeting cellular cathepsins inhibits hepatitis E virus entry 
773 1 8 |g volume:80  |g year:2024  |g number:5  |g month:10  |g pages:1239-1251  |g extent:13  |a Targeting cellular cathepsins inhibits hepatitis E virus entry 
856 4 0 |u https://doi.org/10.1097/HEP.0000000000000912  |x Verlag  |x Resolving-System  |z kostenfrei  |3 Volltext 
856 4 0 |u https://journals.lww.com/hep/fulltext/2024/11000/targeting_cellular_cathepsins_inhibits_hepatitis_e.26.aspx  |x Verlag  |z kostenfrei  |3 Volltext 
951 |a AR 
992 |a 20241126 
993 |a Article 
994 |a 2024 
998 |g 1186079657  |a Dao Thi, Viet Loan  |m 1186079657:Dao Thi, Viet Loan  |d 910000  |d 911700  |e 910000PD1186079657  |e 911700PD1186079657  |k 0/910000/  |k 1/910000/911700/  |p 11 
998 |g 1214598528  |a Fu, Rebecca Menhua  |m 1214598528:Fu, Rebecca Menhua  |d 910000  |d 911700  |e 910000PF1214598528  |e 911700PF1214598528  |k 0/910000/  |k 1/910000/911700/  |p 6 
999 |a KXP-PPN1909529648  |e 4622377845 
BIB |a Y 
SER |a journal 
JSO |a {"name":{"displayForm":["Mara Klöhn, Thomas Burkard, Juliana Janzen, Jil A. Haase, André Gömer, Rebecca Fu, George Ssebyatika, Maximilian K. Nocke, Richard J.P. Brown, Thomas Krey, Viet Loan Dao Thi, Volker Kinast, Yannick Brüggemann, Daniel Todt, Eike Steinmann"]},"recId":"1909529648","note":["Gesehen am 26.11.2024"],"origin":[{"dateIssuedDisp":"November 2024","dateIssuedKey":"2024"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"id":{"doi":["10.1097/HEP.0000000000000912"],"eki":["1909529648"]},"language":["eng"],"title":[{"title":"Targeting cellular cathepsins inhibits hepatitis E virus entry","title_sort":"Targeting cellular cathepsins inhibits hepatitis E virus entry"}],"person":[{"given":"Mara","display":"Klöhn, Mara","family":"Klöhn","role":"aut"},{"role":"aut","family":"Burkard","display":"Burkard, Thomas","given":"Thomas"},{"display":"Janzen, Juliana","family":"Janzen","given":"Juliana","role":"aut"},{"role":"aut","family":"Haase","display":"Haase, Jil A.","given":"Jil A."},{"role":"aut","given":"André","family":"Gömer","display":"Gömer, André"},{"family":"Fu","display":"Fu, Rebecca Menhua","given":"Rebecca Menhua","role":"aut"},{"role":"aut","family":"Ssebyatika","display":"Ssebyatika, George","given":"George"},{"role":"aut","given":"Maximilian K.","display":"Nocke, Maximilian K.","family":"Nocke"},{"role":"aut","given":"Richard J. P.","family":"Brown","display":"Brown, Richard J. P."},{"family":"Krey","display":"Krey, Thomas","given":"Thomas","role":"aut"},{"display":"Dao Thi, Viet Loan","family":"Dao Thi","given":"Viet Loan","role":"aut"},{"role":"aut","family":"Kinast","display":"Kinast, Volker","given":"Volker"},{"role":"aut","given":"Yannick","display":"Brüggemann, Yannick","family":"Brüggemann"},{"family":"Todt","display":"Todt, Daniel","given":"Daniel","role":"aut"},{"display":"Steinmann, Eike","family":"Steinmann","given":"Eike","role":"aut"}],"physDesc":[{"noteIll":"Illustrationen","extent":"13 S."}],"relHost":[{"recId":"268132003","pubHistory":["1.1981 -"],"note":["Gesehen am 28.02.08"],"disp":"Targeting cellular cathepsins inhibits hepatitis E virus entryHepatology","part":{"issue":"5","extent":"13","year":"2024","text":"80(2024), 5 vom: Okt., Seite 1239-1251","pages":"1239-1251","volume":"80"},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"subtitle":"official journal of the American Association for the Study of Liver Diseases","title":"Hepatology","title_sort":"Hepatology"}],"id":{"doi":["10.1002/(ISSN)1527-3350"],"eki":["268132003"],"issn":["1527-3350"],"zdb":["1472120-X"]},"language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"origin":[{"dateIssuedDisp":"1981-","publisherPlace":"[Alphen aan den Rijn] ; Philadelphia, Pa. ; New York [u.a.]","publisher":"Wolters Kluwer Health ; Saunders ; Wiley Interscience","dateIssuedKey":"1981"}]}]} 
SRT |a KLOEHNMARATARGETINGC2024